A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

NCT00096941 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Cancers

Interventions

DRUG: Pertuzumab

Sponsor

Genentech, Inc.